Precigen (PGEN) Osake Kurssi

Precigen Inc is primarily active in the biotechnology industry. As a leading biotech company, Precigen focuses on developing advanced gene and cell therapies, genetic medicines, and agricultural biotechnology solutions. The company harnesses the power of innovative gene editing platforms to address significant unmet needs in healthcare and food production sectors. Precigen Inc leverages its cutting-edge technologies and extensive expertise to create transformative solutions for various genetic disorders, chronic diseases, and sustainable agriculture practices. With its commitment to innovation and scientific progress, Precigen Inc continues to play a vital role in shaping the biotechnology landscape.

The main competitors of Precigen Inc in the market include companies like Intrexon Corporation, Editas Medicine, CRISPR Therapeutics, and Sangamo Therapeutics.

Precigen Inc, formerly known as Intrexon Corporation, is a biotechnology company based in Germantown, Maryland. Established in 1998, Precigen focuses on applying synthetic biology to solve complex problems across various industries. The company is driven by a mission to create biologically-based solutions to improve the quality of life and promote sustainability. Precigen has expertise in the development and commercialization of advanced gene and cellular therapies, as well as agricultural biotech solutions. With its innovative approach and cutting-edge technologies, Precigen has established itself as a leader in the field of synthetic biology, continuously striving to push boundaries and make a positive impact on the world.

Precigen Inc, formerly known as Intrexon Corporation, has achieved several noteworthy milestones throughout its history. The company, a leader in synthetic biology, has successfully developed and commercialized various advanced technologies and solutions. Precigen Inc has made significant breakthroughs in the areas of gene and cell therapy, as well as synthetic gene technologies. These accomplishments include the successful clinical trials of their CAR-T therapy candidates, the development of their UltraVector® platform, and the creation of novel genetically modified organisms. Precigen Inc's continuous dedication to innovation and cutting-edge science has positioned them as one of the prominent players in the field.

Precigen Inc is primarily present in the United States and has its headquarters in Germantown, Maryland.

Precigen Inc represents a strong commitment to innovation, integrity, and social responsibility. As a leading biotechnology company, Precigen pioneers advancements in the field of genetic research. With a dedicated focus on developing therapies and solutions for human health, they prioritize scientific excellence and cutting-edge technology. Led by a team of experts, Precigen emphasizes collaboration and strategic partnerships to achieve their mission of transforming lives through innovative healthcare solutions. Through their dedication to improving global health outcomes and their unwavering dedication to their core values, Precigen Inc stands as a trusted name in the biotech industry.

Analyytikot asettavat tällä hetkellä Precigen-osakkeelle keskimääräisen tavoitehinnan 18,00 USD (mediaani: 18,00 USD), mikä merkitsee +130,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 9 analyytikkoarvioon.

Precigen Analyytikkojen kursstavoitteet 2026

9 analyytikkoa arvioi tällä hetkellä Precigen-osaketta: 7 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Precigen-yhtiöltä 232,88 M USD liikevaihtoa ja 0,16 USD osakekohtaista tulosta.

Precigen Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Precigen-osake noteerataan hintaan 6,78 EUR (7,78 USD).

Precigen-osake (PGEN) on listattuna 5 pörssissä, muun muassa: NASDAQ (PGEN), SIX (Zürich) (I5X.SW), Frankfurt (I5X), München (I5X.MU), Düsseldorf (I5X.DU).

Precigen Inc, founded in 2000, is a biotechnology company headquartered in Germantown, Maryland. The company specializes in the development and application of gene editing technologies used in the therapy of severe diseases and genetic disorders. Precigen's business model is based on four main areas: therapeutic product development, agricultural biotechnology, industrial biotechnology, and research and development of genomic technology. Precigen develops therapeutics aimed at curing or alleviating serious diseases such as cancer and genetic disorders using its proprietary gene editing technology platforms like UltraPrecise, ActoBiotics, and X-Press. The company also works in agricultural biotechnology to develop innovative solutions for improving agricultural yields and promoting sustainable farming. In industrial biotechnology, Precigen leverages its expertise to contribute to the development of renewable energy and biofuels. The company explores and develops new technologies in genomics for diagnostic, therapeutic, and disease prevention purposes. Precigen emphasizes the ethical and social aspects of genetic research. Additionally, the company offers products and services based on its technology platforms, such as UltraVector, a proprietary vector design tool that supports DNA construction and gene editing processes. Precigen also holds a license for obtaining plasmid DNA, which helps reduce costs in the production of therapeutics or biotherapeutics. Overall, Precigen has developed a wide range of technologies and applications to assist customers in overcoming complex challenges in various fields, with a focus on gene editing technology and its applications in therapy, agriculture, industrial biotechnology, and genomic research.

odotettu liikevaihto Precigen on 232,88 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Precigen on 49,53 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Precigen:n hinta-voitto-suhde (P/E) on tällä hetkellä 49,16. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Precigen-osakkeen arvostusta.

Precigen:n hinta-myynti-suhde (P/S) on tällä hetkellä 10,46. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Precigen-osakkeen arvostuskennuslukuna.

Precigen:n Eulpool-laatuscore on 2/10.

Precigen:n ISIN on US74017N1054. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Precigen:n WKN on A2PZG1. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Precigen:n ticker on PGEN. Tämä pörssinoteeraus käytetään Precigen-osakkeiden kauppaan pörssissä.

Precigen maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Precigen kuuluu sektoriin 'Terveydenhuolto'.

Precigen:n osingot jaetaan valuutassa USD.